Frontiers in Oncology
Galectin-9, FABP4 and pentraxin-3 are associated with myocardial dysfunction and discriminate chemotherapy-related cardiac dysfunction in anthracycline-treated breast cancer: a single-centre retrospective study
Background Anthracycline-based chemotherapy improves breast cancer outcomes but may cause cancer therapy-related cardiac dysfunction (CTRCD). Biomarkers reflecting inflammatory and metabolic myocardial stress may complement imaging surveillance, but the combined value of galectin-9 (Gal-9), fatty-acid-binding protein 4 (FABP4) and pentraxin-3 (PTX-3) is unclear. Objective This study aimed to evaluate whether serum Gal-9, FABP4 and PTX-3 are associated with myocardial dysfunction and discriminate CTRCD. Methods This …